Browsing Tag
Oncolytics Biotech
4 posts
Oncolytics maps accelerated approval path for pelareorep while cash drops to $4.1m
FDA feedback could speed pelareorep toward pivotal colorectal cancer testing, but Oncolytics’ $4.1m cash balance puts financing in focus.
Is pelareorep gaining traction? Oncolytics Biotech’s updated GOBLET data draws investor focus to third-line anal cancer
Find out why Oncolytics Biotech’s updated GOBLET cohort 4 data is drawing investor attention to pelareorep’s role in third-line anal cancer.
Oncolytics Biotech signs $20m share purchase deal with Alumni Capital to advance pelareorep development
Oncolytics Biotech inks $20M share deal with Alumni Capital to support pelareorep trials in breast and pancreatic cancer. Read how the biotech firm is advancing.
Oncolytics Biotech advances pancreatic cancer study following regulatory approval
Oncolytics Biotech has achieved a critical milestone in its efforts to transform pancreatic cancer treatment, with Germany’s Paul-Ehrlich-Institute…